HLS Therapeutics Inc. (OTCMKTS:HLTRF – Get Free Report)’s share price was up 0.3% on Wednesday . The company traded as high as $3.16 and last traded at $3.1599. Approximately 4,000 shares changed hands during trading, an increase of 366% from the average session volume of 859 shares. The stock had previously closed at $3.15.
HLS Therapeutics Stock Performance
The firm has a fifty day moving average price of $3.28 and a 200-day moving average price of $3.32.
HLS Therapeutics Company Profile
HLS Therapeutics is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription products for niche therapeutic markets. Headquartered in Mississauga, Ontario, the company builds its portfolio through strategic licensing agreements and in-house development, with an emphasis on therapies that address unmet needs in neurology and rare disorders.
The company’s marketed offering includes treatments for neurological conditions, most notably primary periodic paralysis, for which it commercializes dichlorphenamide (Keveyis) in North America.
Featured Articles
- Five stocks we like better than HLS Therapeutics
- Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore
- Why Kroger’s Pullback Could Be a Gift for Patient Investors
- Why Palantir’s Google Cloud Deal Could Change the Debate
- AI’s Power Problem Is Turning Nuclear Stocks Into a Bigger Market Story
Receive News & Ratings for HLS Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HLS Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
